# A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

> **NCT07728396** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 72 (actual)

## Conditions studied

- COVID - 19

## Interventions

- **BIOLOGICAL:** GC4006A
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT07728396
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728396, "A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07728396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*